Structure-based design and engineering of a nontoxic recombinant pokeweed antiviral protein with potent anti-human immunodeficiency virus activity

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 3, 2003, Pages 1052-1061

  Uckun, Fatih M ^a,b   Rajamohan, Francis ^a,b   Pendergrass, Sharon ^b   Ozer, Zahide ^b   Waurzyniak, Barbara ^a,c   Mao, Chen ^b  

^a Parker Hughes Cancer Center   (United States)

^b PARKER HUGHES INSTITUTE   (United States)

^c Paradigm Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POKEWEED ANTIVIRUS PROTEIN; RECOMBINANT PROTEIN; RIBOSOME RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS PROTEIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; BOLUS INJECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; ESCHERICHIA COLI; EXPERIMENTAL MODEL; GENETIC ENGINEERING; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR MODEL; MOUSE; MOUSE STRAIN; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHENOTYPE; POKEWEED; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; VIRUS MORPHOLOGY; VIRUS MUTATION; VIRUS RECOMBINANT;

ANILINE COMPOUNDS; ANIMALS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DESIGN; IMMUNOBLOTTING; MICE; MICE, INBRED BALB C; MICE, SCID; MODELS, MOLECULAR; N-GLYCOSYL HYDROLASES; PLANT PROTEINS; PLAQUE ASSAY; PLASMIDS; PROTEIN ENGINEERING; PURINES; RECOMBINANT PROTEINS; RNA, VIRAL;

EID: 0037416981     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.3.1052-1061.2003     Document Type: Article

References (38)

1. Bell, J. A., W. J. Becktel, U. Sauer, W. A. Baase, and B. W. Matthews. 1992. Dissection of helix capping in T4 lysozyme by structural and thermodynamic analysis of six amino acid substitutions at Thr 59. Biochemistry 31:3590-3596.
2. Briones, C., V. Soriano, and J. Gonzalez-Lahoz. 2000. Prevalence of drug-resistant HIV-1 genotypes in heavily pre-treated patients on current virological failure. AIDS 14:1659-1660.
3. Erice, A., H. H. Balfour, Jr., D. E. Myers, V. L. Leske, K. J. Sannerud, V. Kuebelbeck, J. D. Irvin, and F. M. Uckun. 1993. Anti-human immunodeficiency virus type 1 activity of an anti-CD4 immunoconjugate containing pokeweed antiviral protein. Antimicrob. Agents Chemother. 37:835-838.
4. Freedberg, K. A., E. Losina, M. C. Weinstein, A. D. Paltiel, C. J. Cohen, G. R. Seage, D. E. Craven, H. Zhang, A. D. Kimmel, and S. J. Goldie. 2001. The cost effectiveness of combination antiretroviral therapy for HIV disease. N. Engl. J. Med. 344:824-831.
5. Gottlieb, M. S. 2001. AIDS - past and future. N. Engl. J. Med. 344:1788-1791.
6. Irvin, J. D., and F. M. Uckun. 1992. Pokeweed antiviral protein: ribosome inactivation and therapeutic applications. Pharmacol. Ther. 55:279-302.
7. Izopet, J., A. Bicart-See, C. Pasquier, K. Sandres, E. Bonnet, B. Marchou, J. Puel, and P. Massip. 1999. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine. J. Med. Virol. 59:507-511.
8. Kurinov, I., F. Rajamohan, T. Venkatachalam, and F. M. Uckun. 1999. X-ray crystallographic analysis of the structural basis for the interaction of pokeweed antiviral protein with guanine residues of ribosomal RNA. Protein Sci. 8:2399-2405.
9. Kurinov, I. V., D. E. Myers, J. D. Irvin, and F. M. Uckun. 1999. X-ray crystallographic analysis of the structural basis for the interactions of pokeweed antiviral protein with its active site inhibitor and ribosomal RNA substrate analogs. Protein Sci. 8:1765-1772.
10. Kuritzkes, D. R., A. Sevin, B. Young, M. Bakhtiari, H. Wu, M. St. Clair, E. Connick, A. Landay, J. Spritzler, H. Kessler, M. M. Lederman, et al. 2000. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immuno-deficiency virus type 1 isolates from AIDS Clinical Trials Group Protocol 315. J. Infect. Dis. 181:491-497.
11. Liu, R., R. K. Narla, I. Kurinov, B. Li, and F. M. Uckun. 1999. Increased hydroxyl radical production and apoptosis in PC12 neuron cells expressing the gain-of-function mutant G93A SOD1 gene. Radiation Res. 151:133-141.
12. Matthews, B. W. 1995. Studies on protein stability with T4 lysozyme. Adv. Protein Chem. 46:249-278.
13. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
14. O'Brien, W. A. 2000. Resistance against reverse transcriptase inhibitors. Clin. Infect. Dis. 30(Suppl. 2):S185-S192.
15. Picard, V., E. Angelini, A. Maillard, E. Race, F. Clavel, G. Chene, F. Ferchal, and J. M. Molina. 2001. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J. Infect. Dis. 184:781-784.
16. Pillay, D., S. Taylor, and D. D. Richman. 2000. Incidence and impact of resistance against approved antiretroviral drugs. Rev. Med. Virol. 10:231-253.
17. Rajamohan, F., S. Doumbia, C. Engstrom, S. Pendergrass, D. Maher, and F. M. Uckun. 2000. Expression of biologically active recombinant pokeweed antiviral protein in methylotrophic yeast Pichia pastoris. Protein Expression Purif. 18:193-201.
18. Rajamohan, F., C. R. Engstrom, T. J. Denton, L. A. Engen, I. Kourinov, and F. M. Uckun. 1999. High level expression and purification of biologically active recombinant pokeweed antiviral protein. Protein Expression Purif. 16:359-368.
19. Rajamohan, F., I. Kurinov, T. Venkatachalam, and F. M. Uckun. 1999. Deguanylation of human immunodeficiency virus (HIV-1) RNA by recombinant pokeweed antiviral protein. Biochem. Biophys. Res. Commun. 263:419-424.
20. Rajamohan, F., M. Pugmire, I. Kurinov, and F. M. Uckun. 2000. Modeling and alanine-scanning mutagenesis studies of recombinant pokeweed antiviral protein. J. Biol. Chem. 275:3382-3390.
21. Rajamohan, F., T. K. Venkatachalam, J. D. Irvin, and F. M. Uckun. 1999. Pokeweed antiviral protein isoforms PAP-I, PAP-II, and PAP-III depurinate RNA of human immunodeficiency virus (HIV-1). Biochem. Biophys. Res. Commun. 260:453-458.
22. Rajamohan, F., C. Mao, and F. M. Uckun. 2001. Binding interactions between the active center cleft of recombinant pokeweed antiviral protein and the α-sarcin/ricin stem loop of ribosomal RNA. J. Biol. Chem. 276:24075-24081.
23. Rajamohan, F., Z. Ozer, C. Mao, and F. M. Uckun. 2001. Active center cleft residues of pokeweed antiviral protein mediate its high affinity binding to the ribosomal protein L3. Biochemistry 40:9104-9114.
24. Rey, D., M. P. Schmitt, M. Partisani, G. Hess-Kempf, V. Krantz, E. de Mautort, C. Bernard-Henry, M. Priester, C. Cheneau, and J. M. Lang. 2001. Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. J. Acquir. Immune Defic. Syndr. 27:459-462.
25. Richman, D. D. 2001. HIV chemotherapy. Nature 410:995-1001.
26. Ross, L., A. Scarsella, S. Raffanti, K. Henry, S. Becker, R. Fisher, Q. Liao, A. Hirani, N. Graham, M. St. Clair, and J. Hernandez. 2001. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens. AIDS Res. Hum. Retrovir. 17:1107-1115.
27. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. Proc. Natl. Acad. Sci. USA 74:5463-5467.
28. Sepkowitz, K. A. 2001. AIDS - the first 20 years. N. Engl. J. Med. 344:1764-1772.
29. Shafer, R. W., and D. A. Vuitton. 1999. Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomed. Pharmacother. 53:73-86.
30. Starr, S. E., C. V. Fletcher, S. A. Spector, F. H. Yong, T. Fenton, R. C. Brundage, D. Manion, N. Ruiz, M. Gersten, M. Becker, J. McNamara, L. M. Mofenson, L. Purdue, S. Siminski, B. Graham, D. M. Kornhauser, W. Fiske, C. Vincent, H. W. Lischner, W. M. Dankner, P. M. Flynn, et al. 1999. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N. Engl. J. Med. 341:1874-1881.
31. Suzuki, K., G. R. Kaufmann, M. Mukaide, P. Cunningham, C. Harris, L. Leas, M. Kondo, M. Imai, S. L. Pett, R. Finlayson, J. Zaunders, A. Kelleher, and D. A. Cooper. 2001. Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine. AIDS Res. Hum. Retrovir. 17:1293-1296.
32. Uckun, F. M., R. Narla, T. Zeren, Y. Yanishevski, D. E. Myers, B. Waurzyniak, O. Ek, E. Schneider, Y. Messinger, L. M. Chelstrom, R. Gunther, and W. Evans. 1998. In vivo toxicity, pharmacokinetics, and anti-cancer activity of genistein conjugated to human epidermal growth factor. Clin. Cancer Res. 4:1125-1134.
33. Uckun, F. M., L. M. Chelstrom, L. Tuel-Ahlgren, I. Dibirdik, J. D. Irvin, M. C. Langlie, and D. E. Myers. 1998. TXU (anti-CD7)-pokeweed antiviral protein as a potent inhibitor of human immunodeficiency virus. Antimicrob. Agents Chemother. 42:383-388.
34. Uckun, F. M., S. Qazi, S. Pendergrass, E. Lisowski, B. Waurzyniak, C. L. Chen, and T. Venkatachalam. 2002. In vivo toxicity, pharmacokinetics, and anti-HIV activity of stavudine-5′[P-bromophenyl methoxyalaninyl phosphate] (stampidine) in mice. Antimicrob. Agents Chemother. 46:3428-3436.
35. Venturi, G., L. Romano, M. Catucci, M. L. Riccio, A. De Milito, A. Gonnelli, M. Rubino, P. E. Valensin, and M. Zazzi. 1999. Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors. Eur. J. Clin. Microbiol. Infect. Dis. 18:274-282.
36. Yim, H. S., J. H. Kang, P. B. Chock, E. R. Stadtman, and M. B. Yim. 1997. A familial amyotrophic lateral sclerosis-associated A4V Cu, Zn-superoxide dismutase mutant has a lower Km for hydrogen peroxide. Correlation between clinical severity and the Km value. J. Biol. Chem. 272:8861-8863.
37. + cells by monoclonal antibodies. Nature 347:92-95.
38. Zhang, X. J., W. A. Baase, and B. W. Matthews. 1992. Multiple alanine replacements within alpha-helix 126-134 of T4 lysozyme have independent, additive effects on both structure and stability. Protein Sci. 1:761-776.